Nevertheless, MetS MPs act via other pathways, including but not limited to Fas/FasL, to increase vascular inflammation and enhance release of vasodilator agents (NO, prostacyclins) which participate in decreasing the Emax (hypo-reactivity). The gene discussed is FAS; the disease is metabolic syndrome.